Which lab assays are used to accurately diagnose early HIV infection?

Answer

A key feature of HIV infection is the prolonged clinical latency that occurs prior to significant immune deficiency.^{[5, 6, 7, 8, 9]}During this period, which is highly variable but generally lasts several years from the time of initial infection, the individual may exhibit few or no symptoms but is still able to transmit the infection to others. Early detection is important to minimize these risks.

Accurate diagnosis of HIV infection has evolved over time and has historically relied on detection of antibodies specific to HIV-1 or HIV-2 infection. The period immediately following HIV infection, before the development of antibodies, is the “window period” during which an antibody test result may be negative. Newer fourth-generation HIV tests combine antibody and antigen detection. These combination immunoassays allow earlier HIV detection, as they detect both HIV-1 and HIV-2 antibodies, as well as HIV-1 p24 antigen.^[10]The p24 antigen is a viral capsid protein that arises in early infection, before development of HIV antibodies.

Importantly, clinicians should be aware that HIV testing should include assays that are specific for both HIV-1 and HIV-2. Most worldwide HIV infections are due to HIV-1. HIV-2 should be considered in individuals from West Africa or in persons with sex partners from West Africa. Some HIV antibody tests are specific only for HIV-1 antibodies. HIV-2 should also be considered in people with clinical evidence of HIV infection who are HIV-1–negative or have indeterminate testing results. Monitoring HIV-2 infection is difficult, as available viral load testing is specific for HIV-1.

Did this answer your question?

Yes No

Additional feedback? (Optional)

Thank you for your feedback!

World Health Organization. Global Health Observatory (GHO) data: HIV/AIDS. Available at https://www.who.int/gho/hiv/en/. Accessed: May 8, 2019.
Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS. 2012 Mar. 7 (2):99-105. [Medline].
The Lancet Hiv. U=U taking off in 2017. Lancet HIV. 2017 Nov. 4 (11):e475. [Medline].
Centers for Disease Control and Prevention. Pre-Exposure Prophylaxis (PrEP). Available at https://www.cdc.gov/hiv/risk/prep/index.html. November 1, 2018; Accessed: May 8, 2019.
Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med. 1993 Feb 4. 328(5):327-35. [Medline].
Weber J. The pathogenesis of HIV-1 infection. Br Med Bull. 2001. 58:61-72. [Medline].
Frazer IH, Mackay IR, Crapper RM, et al. Immunological abnormalities in asymptomatic homosexual men: correlation with antibody to HTLV-III and sequential changes over two years. Q J Med. 1986 Oct. 61(234):921-33. [Medline].
Schechter MT, Boyko WJ, Craib KJ, et al. Effects of long-term seropositivity to human immunodeficiency virus in a cohort of homosexual men. AIDS. 1987 Jul. 1(2):77-82. [Medline].
Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003 Sep 5. 17(13):1871-9. [Medline].
Centers for Disease Control and Prevention and Association of Public Health Laboratories. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Available at http://dx.doi.org/10.15620/cdc.447. June 27, 2014; Accessed: April 27, 2019.
Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000 Mar 30. 342 (13):921-9. [Medline].
Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016 Sep 1. 375 (9):830-9. [Medline].
FDA-Approved Rapid HIV Antibody Screening Tests. Available at http://1.usa.gov/iB5YeN.
Orkuma JA, Egesie JO, Banwat EB, Ejele AO, Orkuma JH, Bako IA. HIV screening in blood donors: rapid diagnostic test versus enhanced ELISA. Niger J Med. 2014 Jul-Sep. 23(3):192-200. [Medline].
Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at http://1.usa.gov/jmqQDU. Accessed: April 27, 2019.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://1.usa.gov/j7Fwpq. Accessed: April 27, 2019.
Mann JK, Chopera D, Omarjee S, Kuang XT, Le AQ, Anmole G, et al. Nef-mediated down-regulation of CD4 and HLA class I in HIV-1 subtype C infection: Association with disease progression and influence of immune pressure. Virology. 2014 Sep 2. 468-470C:214-225. [Medline].
Hull MW, Rollet K, Odueyungbo A, Saeed S, Potter M, Cox J, et al. Factors Associated With Discordance Between Absolute CD4 Cell Count and CD4 Cell Percentage in Patients Coinfected With HIV and Hepatitis C Virus. Clin Infect Dis. 2012 Jun. 54(12):1798-1805. [Medline].
Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997 Jun 15. 126(12):946-54. [Medline].
Rodríguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006 Sep 27. 296(12):1498-506. [Medline].
Mills EJ, Bakanda C, Birungi J, Yaya S, Ford N. The prognostic value of baseline CD4 cell count beyond 6 months of antiretroviral therapy in HIV positive patients in Uganda. AIDS. 2012 Apr 21. [Medline].
Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007 Feb 1. 44 (3):441-6. [Medline].
Palella FJ Jr, Armon C, Chmiel JS, Brooks JT, Hart R, Lichtenstein K, et al. CD4 cell count at initiation of ART, long-term likelihood of achieving CD4 >750 cells/mm3 and mortality risk. J Antimicrob Chemother. 2016 Sep. 71 (9):2654-62. [Medline].
Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013. 8 (12):e81355. [Medline].
INSIGHT START Study Group., Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015 Aug 27. 373 (9):795-807. [Medline].
TEMPRANO ANRS 12136 Study Group., Danel C, Moh R, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015 Aug 27. 373 (9):808-22. [Medline].
Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009. 4 (5):e5575. [Medline].
Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010 Jul 15. 363 (3):257-65. [Medline].
Centers for Disease Control and Prevention (CDC). Revised surveillance case definition for HIV infection--United States, 2014. MMWR Recomm Rep. 2014 Apr 11. 63 (RR-03):1-10. [Medline].
HIV Paediatric Prognostic Markers Collaborative Study., Boyd K, Dunn DT, Castro H, et al. Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. AIDS. 2010 May 15. 24 (8):1213-7. [Medline].
Gale HB, Gitterman SR, Hoffman HJ, Gordin FM, Benator DA, Labriola AM, et al. Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts >=300 cells/μL and HIV-1 suppression?. Clin Infect Dis. 2013 May. 56 (9):1340-3. [Medline].
Girard PM, Nelson M, Mohammed P, Hill A, van Delft Y, Moecklinghoff C. Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?. AIDS. 2013 Nov 13. 27 (17):2759-63. [Medline].
Alidjinou EK, Bocket L, Hober D. Quantification of viral DNA during HIV-1 infection: A review of relevant clinical uses and laboratory methods. Pathol Biol (Paris). 2014 Sep 5. [Medline].
Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA. 2001 Jul 11. 286 (2):171-9. [Medline].
Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010 Dec. 18(5):156-63. [Medline].
Pilcher CD, Ospina-Norvell C, Dasgupta A, Jones D, Hartogensis W, Torres S, et al. The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting. J Acquir Immune Defic Syndr. 2017 Jan 1. 74 (1):44-51. [Medline].
Rothstein SN, Huber KD, Sluis-Cremer N, Little SR. In vitro characterization of a sustained-release formulation for enfuvirtide. Antimicrob Agents Chemother. 2014. 58(3):1797-9. [Medline]. [Full Text].
Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med. 1997 May 19. 102(5B):117-24; discussion 125-6. [Medline].
Karris MY, Anderson CM, Morris SR, Smith DM, Little SJ. Cost Savings Associated with Testing of Antibodies, Antigens, and Nucleic Acids for Diagnosis of Acute HIV Infection. J Clin Microbiol. 2012 Jun. 50(6):1874-8. [Medline].
Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009 Apr 18. 373(9672):1352-63. [Medline]. [Full Text].
Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010 Jul 15. 363(3):257-65. [Medline].
US Department of Health and Human Services. National Institutes of Health. NIH News. Starting Antiretroviral Therapy Earlier Yields Better Clinical Outcomes. Available at http://1.usa.gov/lzSGMc. Accessed: June 8, 2009.
Berk DR, Falkovitz-Halpern MS, Hill DW, et al. Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA. 2005 May 11. 293(18):2221-31. [Medline].
Claassen CW, Diener-West M, Mehta SH, Thomas DL, Kirk GD. Discordance Between CD4+ T-Lymphocyte Counts and Percentages in HIV-Infected Persons With Liver Fibrosis. Clin Infect Dis. 2012 Jun. 54(12):1806-13. [Medline].

Media Gallery

Schematic of enzyme-linked immunoassay (ELISA) technique. 1) viral antigen is bound to a solid substrate. 2) Patient serum with specific antibodies is added and binds to the antigen. 3) After removal of excess antibody, a detection antibody is added, to confirm binding of patient antibodies.

of 1

Author

Philip A Chan, MD, MS Assistant Professor of Medicine, The Warren Alpert Medical School of Brown University; Assistant Professor of Behavioral and Social Sciences, Brown University School of Public Health; Medical Director, Center for HIV/AIDS, Viral Hepatitis, STDs and TB, Rhode Island Department of Health; Director, The Miriam Hospital Pre-exposure Prophylaxis (PrEP) Clinic; Director, The Miriam Hospital Sexually Transmitted Diseases Clinic; Attending Physician, Rhode Island Hospital, The Miriam Hospital, and Women’s and Infants Hospital

Philip A Chan, MD, MS is a member of the following medical societies: American Sexually Transmitted Diseases Association, Infectious Diseases Society of America, National Coalition of STD Directors

Disclosure: Nothing to disclose.

Coauthor(s)

Michaela A Maynard, MPH, MSN, NP-C, WHNP-BC RI Nurse Practitioner, Division of Infectious Diseases, The Miriam Hospital; Research Associate, Department of Medicine, The Warren Alpert Medical School of Brown University

Michaela A Maynard, MPH, MSN, NP-C, WHNP-BC is a member of the following medical societies: American Association of Nurse Practitioners

Disclosure: Nothing to disclose.

Chief Editor

John Bartlett, MD Professor Emeritus, Johns Hopkins University School of Medicine

John Bartlett, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Clinical Pharmacology, American College of Physicians, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, American Thoracic Society, American Venereal Disease Association, Association of American Physicians, Infectious Diseases Society of America, Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Nicholas John Bennett, MBBCh, PhD, MA(Cantab), FAAP Assistant Professor of Pediatrics, Co-Director of Antimicrobial Stewardship, Medical Director, Division of Pediatric Infectious Diseases and Immunology, Connecticut Children's Medical Center

Nicholas John Bennett, MBBCh, PhD, MA(Cantab), FAAP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics

Disclosure: Received research grant from: Cubist<br/>Received income in an amount equal to or greater than $250 from: Horizon Pharmaceuticals, Shire<br/>Medico legal consulting for: Various.

Which lab assays are used to accurately diagnose early HIV infection?

Answer

Related Questions:

References

Tables

Contributor Information and Disclosures